These findings provide evidence for the first time that overexpressed PAK1 is an important molecule participating in the aberrant activation of Raf1/MEK1/ERK signaling pathway and thus may serve as a therapeutic target for ESCC. The gene discussed is MAP2K1; the disease is esophageal squamous cell carcinoma.